ID-PRISM Meetings

ID-PRISM Center is a Collaborative Research and Educational Effort

ID-PRISM hosts meetings with Fred Hutch and University of Washington colleagues to share work in progress and provide training opportunities. The meetings over the next few months will focus on the challenges presented by the coronavirus SARS-CoV-2 and COVID-19 diseases. Our topics will include COVID-19 related biology, epidemiology, treatment, prevention and statistical modeling.

April 3, 2020

Agenda | Activities

ID-PRISM Overview
Drs. Ying Qing Chen, Marco Carone and Alex Leudtke



Population-based assessment of epidemic spread, intervention and mobility effects, policy, advisory panels, social distancing
Dr. Elizabeth “Betz” Halloran

Addressing the COVID-19 Pandemic with CORE Protocols, based on Learnings from EVD
Dr. Thomas Fleming

Seattle Coronavirus Assessment Network (SCAN) COVID-19 (Adaptation of Seattle Flu Study)
Drs. Barbra Richardson and Jim Hughes

Designing COVID-19 prevention and treatment efficacy trials in the face of a rapidly evolving epidemic
Dr. Elizabeth Brown

Modeling of effectiveness of physical distancing interventions: delaying the epidemic or flattening the curve?
Dr. Laura Matrajt

Analysis of the early phase of COVID-19 outbreak in China
Drs. Yifan Zhu and Ying Qing Chen

Network and industry task force on clinical trials for COVID-19
Dr. Deborah Donnell

Quantification of SARS-Cov-2 viral load and diagnostics assays based on UW virology lab data
Dr. Leigh Fisher

World Health Organization Core Protocol for Preventive Vaccine Efficacy Trials
Drs. Yunda Huang, Holly Janes and Peter Gilbert

Risk assessment of accelerated pulmonary comorbidity following SARS-CoV-2 infection using host immune genetic polymorphism
Dr. Lue Ping Zhao

Immune correlates analysis, drug evaluation, and basic science of SARS-Cov-2
Dr. Paul Edlefsen

Survival analysis with doubly interval censored and truncated data for individual-level COVID-19 infection data
Drs. Gary Chan, Fei Gao and Kendrick Li

April 22, 2020




Multivariate Survival Analysis in the Design of COVID Vaccine Trials
Dr. Gary Chan

Evaluating the Effectiveness of Social Distancing Interventions Against COVID-19: Delaying the Epidemic or Flattening the Curve?
Dr. Laura Matrajty

May 20, 2020



This is part one of a two-part presentation. Part two was presented on May 27.

Issues in the Statistical Analysis of Vaccine Efficacy in COVID-19 Vaccine Efficacy Trials
Dr. Peter Gilbert

May 27, 2020



This is part two of a two-part presentation. Part one was presented on May 20.

Comparison of Statistical Methods for Assessing Vaccine Efficacy in COVID-19 Vaccine Efficacy Trials
Dr. Alex Luedtke

June 17, 2020

September 30, 2020



Survival Analysis Using a 5-STAR Approach in Randomized Clinical Trials
Devab V. Mehrotra and Rachel Marceau West
Biostatistics and Research Decision Sciences, Merck

5-STAR (Early online paper)

February 18, 2021



Evaluating Vaccine Efficcy of a Candidate HIV Vaccine vs. Counterfactual Placebo: Immune Marker Mediator Approach
Peter Gilbert, Ph.D.

Design for Actve-Arm Trial with Counterfactual Placebo Incidence Based on Recency Test
Fei, Gao, Ph.D.

Zoom Presentation:

February 25, 2021



Estimation of Dapivirine Vaginal Ring Efficacy in the HOPE Trial
Dr. Alex Leudtke, Department of Statistics, University of Washington

A Bayesian Framework for Inferring Background HIV Incidence: An Application Using Tenofovir Drug Levels
Dr. David V. Glidden, Division of Biostatistics, University of California, San Francisco

PrEP Vacc: A Phase IIB Three-Arm, Two-Stage HIV Prophylactic Vaccine Trial with a Second Randomization to Compare TAF/FTC to TDF/FTC as Pre-Exposure Prophylaxis
Dr. Seila Kansiime, Medical Research Council / Uganda Virus Research Institute, Uganda

graphic of virus

Contact Us For More Information About Our Meetings